Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)
Article in Neurotherapeutics (September 2024)
The most recent citing publications are shown below. View all 48 publications that cite this research output on Dimensions.
Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin
Article in JCI Insight (May 2024)
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
Article in Frontiers in Neurology (January 2024)